Literature and experimental data relevant to the decision to allow a waiver of in vivo bioequivalence testing for the approval of immediate release (IR) solid oral dosage forms containing ranitidine hydrochloride are reviewed. According to the current Biopharmaceutics Classification System (BCS), ranitidine hydrochloride should be assigned to Class III. However, based on its therapeutic and the...

An infusion of ranitidine 0.2 mg/kg/hour abruptly halted a life threatening gastrointestinal haemorrhage in an anuric infant of 30 weeks' gestation.

A comparison was made of the plasma concentrations of ranitidine base in 12 normal volunteers after the administration of 100 mg intravenously and in 6 patients with terminal renal failure after 40 mg intravenously off and then during haemodialysis. The plasma ranitidine concentrations were determined by radioimmunoassay. The results suggest that reduced elimination of the drug occurs in patien...

In the present work, a gastroretentive in situ gelling liquid formulation for controlled delivery of ranitidine was formulated using sodium alginate (low, medium and high viscosity grades), calcium carbonate (source of cations) and ranitidine. Prepared formulations were evaluated for viscosity, buoyancy lag time and buoyancy duration, drug content and in vitro drug release. Formulation variable...

Patients and prescribers have recently been affected by interruptions to the supply of all formulations H2 antagonist ranitidine as a result possible contamination with N-nitrosodimethylamine. Here, Marco Motta Mike Wilcock present outcomes their study evaluating implications these shortages for patients taking from six GP practices in Cornwall.